In 2021, more than 30 new drugs will be listed on the priority review, and oncology drugs are still the main line of domestic innovation

(Health Times reporter Zhao Mengmeng) According to incomplete statistics from Health Times reporters, as of December 28, 2021, at least 31 new drugs (excluding vaccines and traditional Chinese medicines) have passed priority review and been approved for marketing

From the perspective of approved product treatment areas, tumors and rare diseases are the two major areas with the largest number of approved products

In the field of oncology, several significant drugs have been harvested in the Chinese market in 2021

In June 2021, Fosun Kate's Achilles injection was approved, and China ushered in the first CAR-T cell therapy product

Also in June, Rongchang Biological's self-developed vedicitumumab for injection was approved for marketing.

In August, Rongchang Biotechnology reached a cooperation with Seattle Gene, a well-known international biopharmaceutical company.

According to incomplete statistics from Health Times reporters, in the field of rare diseases, there have been 10 new rare disease drugs approved for marketing in China this year, including Kyowa Fermented Kirin's brozoyuumab, Takeda's icatibant acetate and vera.

A total of 5 new rare disease drugs have passed priority review and have been approved for marketing

In December of the same year, the application for import registration of the drug stuximab for injection was approved through the priority review and approval procedure.

Judging from the above-mentioned approval status, rare disease drugs mainly rely on overseas introduction